title: Antiretroviral therapy outcomes of HIV-infected children in the TREAT Asia pediatric HIV observational database.
abstract: BACKGROUND
  We report responses to combination antiretroviral therapy (cART) in the Therapeutics Research, Education, and AIDS Training in Asia Pediatric HIV Observational Database.
  
  
  METHODS
  Children included were those who had received cART (ie, ≥3 antiretrovirals) at <18 years. The analysis was intention-to-treat by the first cART regimen. Median values are provided with interquartile ranges; hazard ratios (HRs) with 95% confidence intervals.
  
  
  RESULTS
  Of the 1655 children included, 50.4% were male, with a median age at cART of 7.0 (3.9-9.8) years and CD4 of 8% (2.0%-15%); 92.5% were started on an NNRTI; median duration of follow-up was 2.9 (1.4-4.6) years. Loss-to-follow-up and death rates were 4.2 (3.7-4.8) and 2.1 (1.7-2.5) per 100 person-years, respectively. At 36 months, median CD4 was 26% (21%-31%); 81% of those with viral load (n = 302) were <400 copies per milliliter. Children who reached CD4 ≥25% within 5 years were more likely to be females (HR: 1.4; 1.2-1.7), start before 18 months old (HR: 3.8; 2.4-6.2), lack a history of monotherapy/dual therapy (HR: 1.7; 1.4-2.5), and have a higher baseline CD4 (per 10% increase: HR: 2; 1.9-2.2).
  
  
  CONCLUSIONS
  These data underscore the need for early diagnosis and cART initiation to preserve immune function.
authors.affiliation: Department of Pediatrics, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand.
authors.forename: Rawiwan
authors.initials: R
authors.lastname: Hansudewechakul
authors.forename: Virat
authors.initials: V
authors.lastname: Sirisanthana
authors.forename: Nia
authors.initials: N
authors.lastname: Kurniati
authors.forename: Thanyawee
authors.initials: T
authors.lastname: Puthanakit
authors.forename: Pagakrong
authors.initials: P
authors.lastname: Lumbiganon
authors.forename: Vonthanak
authors.initials: V
authors.lastname: Saphonn
authors.forename: Nik Khairulddin Nik
authors.initials: NK
authors.lastname: Yusoff
authors.forename: Nagalingeswaran
authors.initials: N
authors.lastname: Kumarasamy
authors.forename: Siew Moy
authors.initials: SM
authors.lastname: Fong
authors.forename: Revathy
authors.initials: R
authors.lastname: Nallusamy
authors.forename: Preeyaporn
authors.initials: P
authors.lastname: Srasuebkul
authors.forename: Matthew
authors.initials: M
authors.lastname: Law
authors.forename: Annette H
authors.initials: AH
authors.lastname: Sohn
authors.forename: Kulkanya
authors.initials: K
authors.lastname: Chokephaibulkit
mesh_terms: D000293:Adolescent; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D001208:Asia / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D016208:Databases, Factual; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D006801:Humans; D007223:Infant; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents